首页 | 本学科首页   官方微博 | 高级检索  
     

唑来膦酸在恶性肿瘤骨转移中的临床应用
引用本文:胡霜霜,童卫杭,王婷,胡范文,孙笑,常子倩. 唑来膦酸在恶性肿瘤骨转移中的临床应用[J]. 中国药师, 2015, 0(9): 1568-1570
作者姓名:胡霜霜  童卫杭  王婷  胡范文  孙笑  常子倩
作者单位:第二炮兵总医院 北京 100088;第二炮兵总医院;第二炮兵总医院;第二炮兵总医院;第二炮兵总医院;第二炮兵总医院
摘    要:摘 要骨转移是恶性肿瘤常见并发症之一,在乳腺癌、肺癌、前列腺癌等发病率高达30% 85%。骨转移导致的持续疼痛及爆发痛,严重影响患者的生活质量。唑来膦酸是第三代双膦酸盐类药物,主要通过抑制破骨细胞的活性和诱导破骨细胞凋亡来抑制骨吸收。唑来膦酸治疗恶性肿瘤骨转移也越来越受到关注,并有良好的应用前景。在此,本文就唑来膦酸治疗恶性肿瘤骨转移的临床研究进展作一综述。

关 键 词:唑来膦酸;恶性肿瘤;骨转移;临床应用
收稿时间:2015-03-18
修稿时间:2015-05-04

Clinical Application of Zoledronic Acid in Bone Metastasis of Malignant Tumor
Hu Shuangshuang,Tong Weihang,Wang Ting,Hu Fanwen,Sun Xiao and Chang Ziqian. Clinical Application of Zoledronic Acid in Bone Metastasis of Malignant Tumor[J]. China Pharmacist, 2015, 0(9): 1568-1570
Authors:Hu Shuangshuang  Tong Weihang  Wang Ting  Hu Fanwen  Sun Xiao  Chang Ziqian
Affiliation:General Hospital of the Second Artillery, Beijing 100088, China;General Hospital of the Second Artillery;General Hospital of the Second Artillery;General Hospital of the Second Artillery;General Hospital of the Second Artillery;General Hospital of the Second Artillery
Abstract:ABSTRACTBone metastasis is the common complication of malignant tumor, especially of breast cancer, lung cancer and prostate cancer etc with the incidence rate above 30% 85%. Cancer patients often suffer from cancer induced bone pain and hypercalcemia, which significantly lower quality of life. Zoledronic acid, as a third generation bisphosphonate, can inhibit bone absorption through inhibiting the activity of osteoclast and inducing the apoptosis of osteoclast. Zoledronic acid used in the treatment of bone metastasis of malignant tumor is paid more and more attention, and shows good application prospect. In this review, the progress in clinical studies on zoledronic acid in the treatment of bone metastasis of malignant tumor was reviewed.
Keywords:Zoledronic acid   Malignant tumor   Bone metastasis   Clinical application
点击此处可从《中国药师》浏览原始摘要信息
点击此处可从《中国药师》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号